SNS812, a broad-spectrum siRNA co-developed by Microbio (Shanghai) and Oneness to treat SARS-CoV-2 infection,was greenlighted by TFDA to proceed with a Ph2 study.

SEQ_NO	1	Date of announcement	2023/06/29	Time of announcement	00:22:15
Subject	SNS812, a broad-spectrum siRNA co-developed by Microbio (Shanghai) and Oneness to treat SARS-CoV-2 infection,wasgreenlighted by TFDA to proceed with a Ph2 study.
Date of events	2023/06/28	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event:2023/06/28 2.Company name:Microbio (Shanghai) Co.,Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):subsidiary 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: (1)New drug name or code: SNS812 (2)Purpose: A. Treatment for COVID-19 infection B. Information Website:has not submitted (3)Planned development stages：Phase II clinical trial/ Phase III clinical trial/NDA (4)Current development stage: A. File application/approved/disapproved/Each of clinical trials (include interim analysis): SNS812, a broad-spectrum siRNA for treatment of SARS- COV-2 infection, has been greenlighted by the TFDA to proceed with the phase 2 study. B. Once disapproved by competent authority or each of clinical trials (include interim analysis) results less than statistically significant sense, the risks and the associated measures the Company may occur: NA C. After obtaining official approval or the results (include interim analysis) which are statistically significant, the future strategy:NA D. Accumulated investment expenditure incurred: No disclosure of investment expenditure at the moment in consideration of future marketing strategies and to protect the interests of the company and investors. (5) Upcoming development plan: Phase II/ III clinical trial A. Scheduled completion date: The actual timeline will depend on the progress of the trial and the review of the regulatory agency. B. Estimate responsibilities: SNS812, a broad-spectrum antiviral siRNA for COVID-19, is developed jointly by Microbio (Shanghai) Co.,Ltd. and Oneness. (6)Market: Based on the data published on June 21, 2023, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 768 million people worldwide and caused more than 6.94 million deaths. With the occurrence of vaccine breakthrough and repeated COVID-19 infections caused by new variants, it is anticipated that the future new variants will lead to periodic global epidemics. Pfizer announced in 2023 that its COVID-19 treatment drug (Paxlovid) has witnessed a significant surge in Q1 sales, soaring from US$1.4 billion in 2022 to US$4.1 billion this year. This far exceeds Wall Street’s expectation of US$2.7 billion, highlighting the immense market demand for COVID-19 treatment drugs. 6.Countermeasures:None 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): (1)On May 31, 2023, an IND application for the phase II clinical trial was submitted to the US Food and Drug Administration (FDA). This phase II clinical trial will enroll participants simultaneously in both the US and Taiwan to expedite the trial’s progress. (2)According to Guidelines by Taipei Exchange on the Material Information Announced by Listed and OTC Companies, new drug development companies shall make public announcement when filing application for clinical trials to domestic or overseas regulatory authorities, receiving approval or disapproval, obtaining the statistical date of endpoints in each clinical trial (including interim analysis), or receiving approval or disapproval on drug license application. (3)It takes considerable time and expenses to develop a new drug of which success can’t be guaranteed. Investors shall bear such investment risk that warrants careful assessment before making investment decisions.